Olema Pharmaceuticals, Inc.
OLMA
$3.06
-$0.12-3.77%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 4.47M | 4.40M | 4.42M | 4.46M | 5.54M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 36.77M | 37.62M | 33.53M | 34.34M | 33.22M |
Operating Income | -36.77M | -37.62M | -33.53M | -34.34M | -33.22M |
Income Before Tax | -33.57M | -34.56M | -30.38M | -30.97M | -26.77M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -33.57M | -34.56M | -30.38M | -30.97M | -26.77M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -33.57M | -34.56M | -30.38M | -30.97M | -26.77M |
EBIT | -36.77M | -37.62M | -33.53M | -34.34M | -33.22M |
EBITDA | -36.65M | -37.53M | -33.44M | -34.25M | -33.13M |
EPS Basic | -0.51 | -0.60 | -0.54 | -0.56 | -0.49 |
Normalized Basic EPS | -0.32 | -0.38 | -0.34 | -0.35 | -0.34 |
EPS Diluted | -0.51 | -0.60 | -0.54 | -0.56 | -0.49 |
Normalized Diluted EPS | -0.32 | -0.38 | -0.34 | -0.35 | -0.34 |
Average Basic Shares Outstanding | 65.79M | 57.26M | 56.28M | 55.57M | 54.78M |
Average Diluted Shares Outstanding | 65.79M | 57.26M | 56.28M | 55.57M | 54.78M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |